Vicore Pharma Holding AB

Vicore Pharma appoints Erik Penser Bank as Certified Adviser

Pressmeddelande   •   Maj 24, 2017 09:00 CEST

Vicore Pharma AB (publ) has entered into an agreement with Erik Penser Bank regarding the service as Certified Adviser. Erik Penser Bank will be appointed Certified Adviser from June 1, 2017.

For further information, please contact
Per Jansson, CEO
Tel: 0709-17 47 46 or e-mail:

This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication May 24, 2017 at. 09:00 CET.

About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to

Vicore Pharmas share is listed on NASDAQ Stockholm, First North under the ticker VICO.
The company´s Certified Adviser is Redeye AB.

Vicore Pharmas affärsstrategi är att leda utvecklingen av nya molekyler med agonistisk verkan på AT2 receptorn för att utveckla framgångsrika läkemedel.